argenx: The FcRn Franchise Is Becoming An Autoimmune Operating System
argenx is developing a unique autoimmune platform that capitalizes on the success of its product VYVGART. The company reported a 63% year-over-year sales growth in the first quarter of 2026 while maintaining a 30% operating margin. Additionally, the recent FDA approval for VYVGART broadens its market potential significantly.
- ▪argenx achieved 63% year-over-year sales growth in Q1 2026.
- ▪The company maintains a 30% operating margin.
- ▪VYVGART's recent FDA approval expands its addressable market.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4907949-argenx-the-fcrn-franchise-is-becoming-an-autoimmune-operating-system"},"author":{"@type":"Person","name":"Equity…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
